Rexahn Pharmaceuticals, Inc. Provides Key Goals for 2012
1/17/2012 8:01:44 AM
ROCKVILLE, Md.--(BUSINESS WIRE)--Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company commercializing oncology and CNS therapeutics, today provided guidance on its key pipeline, scientific and business goals for 2012.
“Rexahn has made the decision to focus in the near term on our oncology program after evaluating how best to apply our resources in order to realize near term value appreciation for our shareholders,” stated Dr. Chang Ahn, Chairman and CEO of Rexahn. “We have sufficient funding to carry the company forward through 2012. The accelerated development of the company’s potent anti-cancer compounds will enable Rexahn to drive short term value while supporting our longer term competitive position.”